SPOTLIGHT: Avanir gains $42M in drug sale


Avanir has gained $42 million from the sale of its schizophrenia drug FazaClo to Ireland's Azur. The move gives Avanir more money to focus on the development of Zenvia for involuntary emotional expression disorder. Azur also agreed to pay up to $10 million more based on a schedule of sales milestones. Report